[Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].
Version 3 of the procedure guideline for (131)I whole-body scintigraphy (WBS) is the counterpart to the procedure guideline for radioiodine therapy (version 3) and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. (131)I WBS 3-6 months after (131)I ablation remains a standard procedure in an endemic area for thyroid nodules and the high frequency of subtotal surgical procedures. Follow-up without (131)I WBS is only justified if the following preconditions are fulfilled: low-risk group pT1-2, pN0 M0 with histopathologically confirmed pN0, (131)I uptake <2%, (131)I WBS during ablation without any suspicious lesion, stimulated thyroglobulin (Tg)-level 3-6 months after ablation <2 ng/mL, and absence of anti-thyroglobulin-antibodies with normal recovery-testing. If patients from the low-risk group show normal (131)I WBS 3-6 months after ablation and stimulated Tg is of <2 ng/mL, there will be no need for additional routine (131)I WBS. If patients from the high-risk group show normal (131)I WBS and stimulated Tg-level of <2 ng/mL 3-6 months after ablation, the follow-up care should include repeated stimulated Tg-measurements. If the Tg-level remains below 2 ng/mL, an additional (131)I WBS will be not necessary. The recommended intervals for stimulated Tg-testing are adapted to the prior intervals for (131)I WBS-testing in the high-risk group. Increased anti-thyroglobulin-antibodies or incomplete recovery-testing make an individual strategy of follow-up care necessary, which include (131)I WBS.
Dietlein
M
M
Kliniken und Polikliniken für Nuklearmedizin der Universität zu Köln, 50924 Köln. markus.dietlein@uni-koeln.de
Dressler
J
J
Eschner
W
W
Grünwald
F
F
Lassmann
M
M
Leisner
B
B
Luster
M
M
Reiners
C
C
Schicha
H
H
Schober
O
O
D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000592:standards; D017410:Practice Guidelines as Topic; D011786:Quality Control; D011877:Radionuclide Imaging; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D051598:Whole Body Imaging / Q000009:adverse effects / Q000379:methods / Q000592:standards*
D007457:Iodine Radioisotopes